Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy
Related Experiment Video
Updated: Oct 20, 2025
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
James Harber1, Tamihiro Kamata1, Catrin Pritchard1
1Cancer Research Centre, University of Leicester College of Life Sciences, Leicester, UK.
Abstract:
Malignant pleural mesothelioma (MPM) is an incurable cancer with a dismal prognosis and few effective treatment options. Nonetheless, recent positive phase III trial results for immune checkpoint blockade (ICB) in MPM herald a new dawn in the fight to advance effective treatments for this cancer. Tumor mutation burden (TMB) has been widely reported to predict ICB in other cancers, but MPM is considered a low-TMB tumor. Similarly, tumor programmed death-ligand 1 (PD-L1) expression has not been proven predictive in phase III clinical trials in MPM. Consequently, the precise mechanisms that determine response to immunotherapy in this cancer remain unknown. The present review therefore aimed to synthesize our current understanding of the tumor immune microenvironment in MPM and reflects on how specific cellular features might impact immunotherapy responses or lead to resistance. This approach will inform stratified approaches to therapy and advance immunotherapy combinations in MPM to improve clinical outcomes further.
Insights
Malignant pleural mesothelioma (MPM) immunotherapy response mechanisms remain unclear. This review explores the tumor immune microenvironment to identify factors influencing treatment effectiveness and resistance in MPM.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited treatment options.
- Recent advances in immune checkpoint blockade (ICB) offer new hope for MPM patients.
- Predictive biomarkers like tumor mutation burden (TMB) and PD-L1 expression have shown limited success in MPM.
Purpose of the Study:
- To review the current understanding of the tumor immune microenvironment (TME) in MPM.
- To identify cellular features within the TME that may predict response or resistance to immunotherapy.
- To inform the development of stratified immunotherapy approaches and combinations for MPM.
Main Methods:
- Literature review and synthesis of existing research on MPM and its TME.
- Analysis of cellular components and their roles in immune response within the MPM microenvironment.
- Evaluation of potential biomarkers and therapeutic strategies.
Main Results:
- MPM is characterized by a complex TME where traditional biomarkers (TMB, PD-L1) are not consistently predictive of immunotherapy response.
- Specific cellular populations and interactions within the TME are likely key determinants of treatment efficacy.
- Understanding these intricate TME dynamics is crucial for optimizing immunotherapy outcomes.
Conclusions:
- The mechanisms driving immunotherapy response in MPM are not fully understood, necessitating further investigation into the TME.
- Targeting specific cellular components or pathways within the MPM TME could enhance immunotherapy effectiveness.
- Future strategies should focus on personalized approaches and combination therapies informed by TME characteristics to improve clinical outcomes in MPM.
Related Concept Videos
02:17The Tumor Microenvironment
01:27Tumor Immunotherapy